By Yadarisa Shabong and Maggie Fick (Reuters) -GSK’s shares fell as much as 7% on Thursday, a day after a U.S. public health agency narrowed its age recommendation for use of respiratory syncytial virus (RSV) vaccines, in a blow to the drugmaker’s ambitions for its new blockbuster medicine. Britain’s GSK launched its RSV vaccine, Arexvy,…
